A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR

Journal of Cancer Research and Clinical Oncology
Jing ZengYi Fang

Abstract

Both CD20 and HLA-DR antigens are highly expressed on a variety of B-cell lymphomas and are therapeutic targets in antibody-based lymphoma therapy. The aim of this study was to evaluate the anti-tumor effect of a bispecific antibody CD20-HLA-DR DVD-Ig on B-cell lymphoma. The gene for bispecific antibody CD20-HLA-DR DVD-Ig was constructed and expressed in FreeStyle™293-F cells, followed by purification. Their functions were characterized for binding to CD20 and HLA-DR and for cytotoxicity against B-cell lymphoma. The bispecific antibody CD20-HLA-DR DVD-Ig was engineered using the DNA fragments for the anti-CD20 rituximab and anti-HLA-DR hL243γ1. The CD20-HLA-DR DVD-Ig bound simultaneously to both CD20 and HLA-DR, induced potent complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) against B-cell lymphoma, and elicited homotypic adhesion and actin reorganization. Treatment of a mixture of human whole blood and Raji cells with CD20-HLA-DR DVD-Ig effectively depleted Raji cells and had a little toxicity against normal B cells. Our data indicated that targeting both CD20 and HLA-DR was an effective way against NHL, suggesting that CD20-HLA-DR DVD-Ig may be a promising therapeutic agent for B-cel...Continue Reading

References

Apr 18, 1985·Nature·U D StaerzM J Bevan
Feb 5, 1999·European Journal of Immunology·C LéveilléW Mourad
Aug 1, 2000·Immunology Today·A B van SprielJ G van De Winkel
Jul 31, 2001·International Journal of Cancer. Journal International Du Cancer·S A KostelnyG J Weiner
Mar 22, 2002·Nature Reviews. Cancer·P Carter
Sep 5, 2002·European Journal of Immunology·Claire LévéilleReem Al-Daccak
Aug 27, 2003·Seminars in Oncology·Michael DechantThomas Valerius
May 25, 2004·Leukemia & Lymphoma·Pier Luigi Zinzani
Oct 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Myron S CzuczmanAntonio J Grillo-López
Jan 15, 2005·Cancer Biotherapy & Radiopharmaceuticals·Cathy LiuSally DeNardo
Feb 1, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Noel LaudiDaniel J Weisdorf
Sep 10, 2005·Nature Biotechnology·Gregory P Adams, Louis M Weiner
Apr 14, 2006·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·M D Pescovitz
Sep 5, 2007·Molecular Immunology·Martin J GlennieRonald P Taylor
Aug 9, 2008·The New England Journal of Medicine·Bruce D Cheson, John P Leonard
Mar 24, 2009·Lancet·Louis M WeinerSoldano Ferrone
Mar 5, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Dafne Müller, Roland E Kontermann
Jun 26, 2010·Blood·Erin Hertlein, John C Byrd
Mar 23, 2012·Nature Reviews. Cancer·Andrew M ScottLloyd J Old
Jun 28, 2012·Methods in Molecular Biology·Enrico DiGiammarinoJunjian Liu
Jun 29, 2012·Protein Engineering, Design & Selection : PEDS·Shu-Ru KuoJen-Sing Liu
Sep 14, 2013·Science·Mark X Sliwkowski, Ira Mellman
Oct 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yvonne KienastMarkus Thomas

❮ Previous
Next ❯

Citations

Apr 15, 2016·Investigational New Drugs·Yaghoub SafdariSafar Farajnia
Jan 11, 2017·MAbs·Ulrich Brinkmann, Roland E Kontermann
Mar 9, 2021·Frontiers in Immunology·Mehdi MohammadiFazel Shokri
Jul 16, 2021·Leukemia & Lymphoma·Adrian Minson, Michael Dickinson
Jun 18, 2019··Wenxin Zhao, Wenxin Zhao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.